Volume 13, Number 6—June 2007
Perspective
Economic Evaluation and Catheter-related Bloodstream Infections
Kate Halton*†
and Nicholas Graves*†
and Nicholas Graves*†Table 6
Ranks of evidence for parameters used in the decision models*
| Evidence ranking | Clinical effectiveness of intervention, n = 8 | Baseline incidence CR-BSI, n = 8 | Attributable mortality, n = 7 | Incidence localized insertion site infection, n = 5 | Cost of CR-BSI, n = 8 | Cost of intervention, n n = 8 |
|---|---|---|---|---|---|---|
| High quality | ||||||
| Rank 1 | 5 | 1 | – | – | 2 | – |
| Rank 2 | 1 | 1 | 1 | – | 1 | 7 |
| Medium quality | ||||||
| Rank 3 | – | 1 | 1 | – | 2 | – |
| Low quality | ||||||
| Rank 4 | 1 | 4 | 4 | 4 | 2 | – |
| Rank 5 | – | 1 | 1 | 1 | – | – |
| Rank 6 | – | – | – | – | – | – |
| Unclear | 1 | – | – | – | 1 | 1 |
*CR-BSI, catheter-related bloodstream infections.
